Fc gamma receptor III (CD16)–Immunoglobulin G fragment crystallizable (IgG Fc) interaction (CD16–IgG Fc)

The CD16–IgG Fc interaction is a pivotal immunological process where the Fc gamma receptor III (CD16) on effector cells binds to the fragment crystallizable (Fc) region of immunoglobulin G (IgG) antibodies (UniProt P08637). This interaction is primarily responsible for mediating antibody-dependent cellular cytotoxicity (ADCC), a critical mechanism by which the innate immune system, particularly natural killer (NK) cells, identifies and destroys antibody-coated target cells such as tumor cells or virally infected cells (PubMed). CD16 exists in two isoforms: CD16a (FcγRIIIA), an activating receptor found on NK cells and macrophages, and CD16b (FcγRIIIB), a GPI-anchored receptor on neutrophils (Wikipedia). The affinity of this interaction is significantly influenced by genetic polymorphisms, most notably the FCGR3A-V158F variant, where the valine (V) allele provides higher binding affinity and is associated with better clinical outcomes in patients receiving monoclonal antibody therapy (NIH). In the pharmaceutical industry, this interaction is a major focus for drug optimization; many therapeutic antibodies, such as margetuximab and obinutuzumab, are engineered through amino acid substitutions or glycoengineering to enhance their affinity for CD16 and boost ADCC (Frontiers in Immunology). Conversely, the interaction can be a source of therapeutic challenges, such as competition with high levels of endogenous IgG or the rapid downregulation of CD16 from the cell surface via ADAM17-mediated shedding during immune activation (PubMed). Understanding and modulating the CD16–IgG Fc interaction remains a cornerstone of modern immunotherapy and the development of next-generation biologics.

Other names

CD16–IgG Fc interactionFcγRIII–IgG Fc interactionFc gamma receptor IIIa–IgG interactionFc gamma receptor IIIb–IgG interactionLow affinity immunoglobulin gamma Fc region receptor III interaction

The interaction involves the binding of the fragment crystallizable (Fc) region of an IgG antibody to the CD16 receptor on effector cells (such as NK cells or macrophages), which triggers intracellular signaling via immunoreceptor tyrosine-based activation motifs (ITAMs) leading to the release of cytotoxic granules (perforin/granzymes) or phagocytosis of the antibody-coated target cell (PubMed, Wikipedia).